7 Best Peptides for Neuroinflammation

What to Know Before Choosing a Peptide for Neuroinflammation

Neuroinflammation is not a single condition. It is a process, one where the brain's resident immune cells shift into a destructive mode and begin releasing signals that damage neurons, disrupt the protective lining around the brain, and drive the cognitive and neurological symptoms that bring people to this topic in the first place. People searching for peptides to address it are coming from many different starting points: TBI recovery, long COVID, early dementia, Parkinson's support, or simply persistent brain fog that no conventional approach has touched.

Every peptide in this guide earned its slot by meeting one criterion: people use it for neuroinflammation, or are actively discussing using it for that goal. That includes compounds available through telemedicine clinics, research-only compounds that exist outside conventional medical channels, and everything in between. Evidence strength is stated honestly for each one, but it is never used as a filter for inclusion. A compound with only community-reported use still belongs here, with its thin evidence described plainly. A compound with published human trials gets that stated equally plainly. The reader deserves the full picture of what people are actually reaching for, not a pre-filtered list shaped by regulatory status.

It is worth stating up front that none of the peptides in this guide hold FDA approval specifically for neuroinflammation. Some are approved for other conditions in other countries, some are available through compounding pharmacies or telemedicine channels, and some exist purely in research contexts. That range is part of the honest picture, and it applies across the list rather than being unique to any single compound.

The seven compounds below are ordered by how prominently each appears in research and real-world use for neuroinflammation, not as a recommendation of one over another. The right compound depends on the specific nature of someone's neuroinflammation, what else they are taking, their health history, and how they weigh the evidence. This guide gives you the map. MyPeptidePal helps you build the plan.

1. BPC-157: For BBB Integrity and Gut-Brain Neuroinflammation

BPC-157, short for Body Protection Compound-157, is a synthetic pentadecapeptide, a chain of 15 amino acids, originally derived from a protein found in gastric juice. It consistently leads the conversation on neuroinflammation peptides because it brings mechanistic specificity and the broadest preclinical evidence base of any compound in this list.

What sets BPC-157 apart for neuroinflammation specifically is its effect on the blood-brain barrier, the tightly regulated biological seal that controls what enters and exits the brain. Think of this barrier as a filter with an extremely selective membrane: when inflammatory assault degrades that membrane, consequences ripple across the entire central nervous system. BPC-157 appears to preserve this barrier by reducing damage to the endothelial cells that form it. It works through a mechanism involving focal adhesion kinase, a structural protein that helps cells grip and hold their shape under stress. When that gripping mechanism is disrupted, the barrier becomes leaky. BPC-157 also inhibits activation of NF-kB, a molecular switch that tells cells to produce pro-inflammatory signals throughout the nervous system. Keeping that switch off reduces the cascade of cytokine release that sustains neuroinflammation.

A second mechanism that draws particular attention is the gut-brain axis. A significant proportion of neuroinflammation in practice is driven or amplified by gut dysfunction. BPC-157 has strong preclinical data for gastrointestinal repair. For people whose brain symptoms are intertwined with GI issues, a pattern common in long COVID and post-viral syndromes, this dual mechanism is part of why BPC-157 is frequently the first compound people try for neuroinflammation.

The honest evidence state: the preclinical data is genuinely broad. Animal studies spanning traumatic brain injury, nerve injury, and neurodegeneration models consistently show anti-inflammatory and neuroprotective effects, with emerging 2024 and 2025 data in TBI and Parkinson's disease models. Human evidence is limited to one unpublished oral study and one retrospective study on intra-articular injections, neither of which constitutes strong clinical proof for neuroinflammation specifically. Long COVID community experience is largely user-reported: people describe meaningful reductions in brain fog, fatigue, and GI symptoms, with some noting that benefits diminish after stopping. People access BPC-157 through research chemical suppliers and, in some cases, compounding pharmacies. For a compound with real mechanistic rationale and encouraging preclinical results, the translation to rigorous human trials remains unfinished.

2. Semax: For Neuroprotection and Post-Injury Brain Recovery

Semax is a synthetic heptapeptide developed at Russia's Institute of Molecular Genetics, built from a fragment of adrenocorticotropic hormone, the pituitary signal that activates the body's stress response. It is one of the most clinically applied peptides for central nervous system conditions anywhere in the world, though not yet through conventional channels in the United States.

Its relevance to neuroinflammation centers on two related actions. First, Semax stimulates the production of neurotrophic factors, the signaling proteins the brain uses to protect, grow, and repair neurons, particularly brain-derived neurotrophic factor, nerve growth factor, and ciliary neurotrophic factor. These factors tend to be depleted in states of chronic neuroinflammation, so restoring them addresses both the inflammatory state and the downstream neuronal damage it causes. Second, Semax suppresses the destructive, pro-inflammatory activity of microglia. It does this through BDNF-TrkB signaling, where BDNF is the neurotrophic factor described above and TrkB is its receptor on the surface of neurons and immune cells. Activating TrkB triggers an internal signaling cascade that shifts microglia away from their inflammatory state and toward a protective one.

Semax is used clinically in Russia and parts of Eastern Europe for stroke recovery, cognitive impairment, and TBI rehabilitation. Small published clinical trials support these applications, though the literature is almost entirely Russian and has seen limited independent replication elsewhere. A practical advantage is its delivery route: intranasal administration provides strong CNS bioavailability by bypassing the blood-brain barrier through the nasal passages, which means the compound reaches the brain without needing to cross the barrier directly. This makes it convenient for regular use and is one reason it recurs in community protocols for brain fog and cognitive clarity.

In the US, Semax was under active FDA review for bulk drug substance status as of mid-2026. It is available through compounding pharmacies and telemedicine clinics operating off-label. User-reported experience from nootropic and biohacker communities is broadly positive, with people citing sharper focus, reduced brain fog, and improved mood. The evidence is a genuine mix: real but geographically concentrated clinical data on one side, and a substantial community-reported base on the other.

3. Selank: For Anxiety-Driven and Stress-Related Neuroinflammation

Selank is a synthetic heptapeptide and a close institutional relative of Semax, also developed at Russia's Institute of Molecular Genetics. Its structure is based on tuftsin, a naturally occurring tetrapeptide involved in immune regulation, with three additional amino acids added to extend its half-life and CNS activity.

Selank's entry point into neuroinflammation is somewhat different from the compounds above. Its primary pharmacological action is anxiolytic, meaning it reduces anxiety. It achieves this through tuftsin receptor activation and modulation of GABAergic signaling, the brain's main inhibitory system that dampens overactive neural activity, alongside serotonin modulation, which influences mood stability and stress response. The neuroinflammation connection operates on two levels. Directly, Selank promotes pro-resolving microglial biology, nudging microglia toward their protective rather than inflammatory phenotype. Indirectly, chronic psychological stress is itself a driver of neuroinflammation: sustained stress-response signaling maintains a low-grade inflammatory state in the CNS, and a compound that reliably reduces that stress load reduces the neuroinflammatory burden alongside it.

Small clinical trials in Russia have examined Selank in anxiety disorders, placing it alongside Semax as one of the only peptides with any published human clinical data touching neuroinflammation-adjacent conditions. That published base is limited and concentrated in Russian literature, with minimal independent replication outside that system. In the US, Selank is available through compounding pharmacies and research chemical suppliers. User-reported experience is consistently positive and notably milder in adverse-event profile compared to some of the more potent compounds on this list. People describe it as calming without sedation, useful for stress-related cognitive fog, and generally well-tolerated. For someone whose neuroinflammation has a strong stress or anxiety component, Selank is the compound most consistently pointed to in community protocols.

4. Cerebrolysin: For Neurotrophic Support and Neurological Repair

Cerebrolysin is unlike anything else on this list in a fundamental way: it is not a single synthesized peptide but a mixture of low-molecular-weight neuropeptide fragments and amino acids derived from porcine brain tissue. Those fragments include compounds that closely resemble brain-derived neurotrophic factor, nerve growth factor, ciliary neurotrophic factor, and glial cell line-derived neurotrophic factor. These are the proteins the brain relies on to maintain, repair, and grow neurons. The practical effect is something like delivering a set of neurotrophic signals simultaneously rather than activating a single molecular target.

Cerebrolysin has been used clinically in Austria, Germany, and parts of Asia for decades, with formal approvals in those regions for stroke, dementia, and traumatic brain injury. It carries more genuine clinical use history than any other compound on this list, though that history exists largely outside the US regulatory framework. European and Asian clinical data, while not always meeting the methodological standards of a modern randomized controlled trial, represents a real body of human use in serious neurological conditions. That distinguishes it from purely preclinical compounds.

In community use, Cerebrolysin has generated some of the most dramatic anecdotal reports of any peptide in the neuroinflammation space, particularly among long COVID patients. People describe reversals of severe brain fog, restored ability to work and exercise, and reductions in CNS inflammation that other interventions had not addressed. That positive experience is real and worth naming. So is the risk profile.

The risk profile here is more significant than for most other compounds in this list. Community reports include cases of autoimmune neuropathy following a single injection, and cases of cholinergic urticaria, a skin and immune reaction triggered by acetylcholine-like activity. There is also a pattern of polarized response: some users experience no benefit at all while others report dramatic improvement. The immune-activating potential of a multi-component biological preparation means it carries a different risk category than a single synthesized peptide. Anyone with underlying autoimmune conditions should approach it with particular caution. Cerebrolysin is administered by injection, typically intramuscular or intravenous, and is available in the US through compounding pharmacies and import channels.

5. VIP: For Microglial Immunomodulation and CNS Inflammation Suppression

Vasoactive Intestinal Peptide, almost universally abbreviated as VIP, is a 28-amino acid neuropeptide that occurs naturally throughout the nervous system, gut, and immune tissues. It has attracted research interest in neuroinflammation because of its mechanistically clean action on the exact process that drives CNS immune overactivation.

VIP's primary mechanism begins at the VPAC1 receptor, a surface protein on microglia and other immune cells that acts as an entry point for VIP's anti-inflammatory signal. When VIP binds to VPAC1, it triggers an increase in cyclic AMP, or cAMP, a chemical messenger inside the cell that can dial inflammation up or down. In this case, the rising cAMP activates an enzyme called protein kinase A, which then suppresses NF-kB. NF-kB is a molecular switch that controls production of pro-inflammatory genes, including those that produce TNF-alpha, a key inflammatory signaling protein, and interleukins 1 beta and 6. In plain terms: VIP activates an internal off-switch for the signaling that tells microglia to keep producing inflammatory signals. The downstream result is a shift from the destructive pro-inflammatory microglial state toward the protective anti-inflammatory state.

The evidence for VIP in neuroinflammation is entirely preclinical as of 2026. It appears consistently in peer-reviewed reviews of peptides with anti-neuroinflammatory potential, with supporting data from rodent models. No published human clinical trial data exists for VIP in this application. It has also attracted research interest in the context of long COVID, particularly for dysautonomia, a dysfunction of the autonomic nervous system, the system that regulates heart rate, digestion, and other automatic functions. Dysautonomia overlaps with neuroinflammatory processes in ways that make VIP mechanistically relevant, though that work remains preliminary. VIP is available in research and compounding contexts and is used by some functional medicine practitioners for immune modulation. The evidence here is preclinical rather than clinical, and anyone considering it should weigh that gap directly.

6. GHK-Cu: For Oxidative Stress and Antioxidant Neuroprotection

GHK-Cu is a copper-binding tripeptide made from three amino acids: glycine, histidine, and lysine. It is endogenous, meaning the human body produces it naturally, and plasma levels decline measurably with age. Most people who have encountered it did so first in the context of skin aging and wound healing, where its regenerative properties have attracted the most research attention. Its relevance to neuroinflammation comes from a different mechanism.

Neuroinflammation is not only a cytokine problem. When microglia shift into their inflammatory state, they also release reactive oxygen species, highly unstable molecules that attack neurons and accelerate structural damage. GHK-Cu activates the Nrf2 pathway, a cellular defense system that functions as a master switch for the body's own antioxidant enzymes. Activating this switch upregulates proteins that neutralize reactive oxygen species and reduce oxidative damage to neurons. GHK-Cu also exerts direct anti-inflammatory effects by reducing pro-inflammatory cytokine production. In neurodegenerative models, where oxidative stress is a persistent secondary injury mechanism, this makes GHK-Cu mechanistically relevant even though it is not primarily thought of as a neuroinflammation compound.

The honest evidence picture: GHK-Cu has strong preclinical data for antioxidant and tissue-regenerative properties, and human data exists for its skin and wound-healing applications. Human data specific to neuroinflammation is largely absent as of 2026. People in longevity and biohacker communities use it for general neuroprotection and anti-aging, and it is available via injectable, topical, and intranasal forms. Community use for neuroinflammation specifically is present but not the primary use case that drives most people to it. It earns its place here because its mechanism addresses a real component of neuroinflammatory damage, oxidative neuronal injury, that most other compounds on this list do not directly target.

7. Thymosin Alpha-1: For Autoimmune-Driven Brain Inflammation

Thymosin Alpha-1, often written as Ta1, is a 28-amino acid peptide produced naturally by the thymus gland. It is the most immunologically specific compound on this list, and that specificity is what makes it relevant to a particular subset of neuroinflammation: the kind driven by autoimmune and T-cell-mediated mechanisms.

Ta1 modulates the immune response by reducing pro-inflammatory cytokines including TNF-alpha, interleukin-1 beta, and interleukin-6. It also expands regulatory T cells, the immune population whose job is to prevent excessive or misdirected immune activation. In CNS contexts, regulatory T cells suppress the T-cell-driven autoimmune processes that damage myelin and neurons in conditions like multiple sclerosis and autoimmune encephalitis. For someone whose neuroinflammation has an autoimmune signature rather than a purely microglia-driven one, this mechanism is more directly relevant than the pathways targeted by most other compounds on this list.

Thymosin Alpha-1 holds formal regulatory approval in some countries as Zadaxin, primarily for hepatitis and cancer-related immune support. That approval establishes a human safety profile that few research peptides can point to. In the US it is used off-label, often in functional and integrative medicine settings. Human data specific to CNS autoimmune neuroinflammation remains emerging rather than established. Community use for this application is smaller and more specialized than for BPC-157 or Semax, and user-reported experience is positive but limited in volume. For the specific profile of autoimmune-driven brain inflammation, Thymosin Alpha-1 is the compound with the most pharmacologically grounded case for inclusion.

How These Peptides Compare

Frequently Asked Questions

Are any of these peptides FDA-approved for neuroinflammation?

None of the peptides in this guide hold FDA approval specifically for neuroinflammation as of 2026. Thymosin Alpha-1 is approved in some countries for hepatitis and cancer-related immune support, and that approval provides a human safety record, but it does not extend to neuroinflammation as a primary indication. Most compounds covered here are research chemicals, compounding pharmacy preparations, or off-label uses. Regulatory status should be confirmed with a qualified healthcare provider before any use.

Why is the human evidence so thin for most of these compounds?

The gap between animal studies and human trials is a persistent feature of neuroinflammation research, not something specific to peptides. Many compounds that show strong results in rodent models fail to replicate in human trials, partly because human neuroinflammation is more complex and variable than the standardized models used in animal research. For peptides specifically, the commercial incentive to fund expensive Phase 2 and Phase 3 trials is low when a compound cannot be patented. That economic reality means most peptides used for neuroinflammation have robust animal data but human evidence limited to small regional trials, retrospective studies, or community-reported use.

Is neuroinflammation the same as regular inflammation elsewhere in the body?

They share the same basic biology but neuroinflammation has distinct features. The central nervous system has its own resident immune cells, microglia, that behave differently from the macrophages driving peripheral inflammation. The blood-brain barrier also means that systemic anti-inflammatory approaches often do not reach the CNS in concentrations sufficient to reduce neuroinflammation directly. This is part of why compounds with CNS-specific delivery, like intranasal Semax or BPC-157's barrier-preserving effects, draw particular interest for this application rather than general anti-inflammatory peptides.

Which of these is most commonly discussed for long COVID brain fog?

BPC-157 and Cerebrolysin are the two compounds that come up most consistently in long COVID community discussions about brain fog and neuroinflammation. BPC-157 is frequently cited for its gut-brain axis mechanism, given that many long haulers experience GI dysfunction alongside neurological symptoms. Cerebrolysin generates more dramatic accounts of recovery but also carries a more significant risk profile, including community-reported cases of autoimmune reactions. Selank and Semax also appear regularly in these discussions for their effects on cognitive clarity and stress-related symptoms. The evidence for any peptide specifically in long COVID remains community-reported rather than the product of controlled trials.

Do any of these compounds work on both inflammation and neuronal repair?

Several of them address both processes simultaneously. Cerebrolysin directly supplies neurotrophic fragments that support neuronal survival, synapse formation, and repair while also reducing inflammation. Semax stimulates production of neurotrophic factors including BDNF and nerve growth factor as its primary mechanism, and the anti-inflammatory effect is partly downstream of that neuroprotective action. BPC-157 addresses repair through its effects on blood vessel growth, barrier integrity, and tissue healing while also suppressing inflammatory signaling. That dual mechanism is part of why these compounds generate interest for serious CNS conditions rather than purely as anti-inflammatory agents.

This content is for informational and educational purposes only. It does not constitute medical advice, diagnosis, or treatment recommendations. MyPeptidePal is not a medical provider. Always consult a qualified healthcare professional before starting, modifying, or stopping any health protocol, supplement regimen, or therapeutic intervention.

Sources

The information in this guide is drawn from the MyPeptidePal knowledge base, which brings together published research, clinical data, and reported real-world use of peptides for neuroinflammation in one place.